Form 4: Esperion Therapeutics Executive Eric Warren Reports Stock Option Grant and Common Stock Acquisition

Chief Commercial Officer Eric Warren of Esperion Therapeutics reports the acquisition of 100,000 shares of common stock and a stock option grant for 150,000 shares.

Summary

• On March 14, 2024, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, reported a transaction involving the acquisition of 100,000 shares of common stock at $0 and a grant of stock options for 150,000 shares.
• The stock options have an exercise price of $2.05 and expire on March 14, 2034.
• The options vest over a four-year period in equal quarterly installments, starting June 15, 2024.
• Following the reported transaction, Warren beneficially owns 168,318 shares of common stock and options for 150,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options could be seen as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of shares and stock options by a key executive could be interpreted as a positive sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
• The vesting schedule of four years with quarterly installments is a typical structure for such grants.
• Comparing the size of the grant to those of executives at similar-sized pharmaceutical companies would provide further context.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of executive confidence.

Key Dates